A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs ID 93/GLA-SE (Primary) ; ID 93
- Indications Tuberculosis
- Focus Adverse reactions
- 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2012 Infectious Disease Research Institute announces the initiation of this trial in a media release.